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Characterisation of immune responses in pancreatic carcinoma patients
after mutant p21 ras peptide vaccination
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Summary This is a study of immune responses generated by mutant ras peptide vaccination of patients with
pancreatic adenocarcinoma. Responding T cells from one patient were cloned and two CD4+ T-lymphocyte
clones (TLC) specific for the 12 Val peptide and restricted by HLA-DR6 or DQ2 were obtained. These class II
molecules have not previously been found to bind or present mutant ras peptides to T cells. The DR6-restricted
TLC showed marked cytotoxicity against autologous target cells pulsed with the 12Val peptide. Target cells
pulsed with the control peptide were not killed. Responding T cells from another patient showed cross-
reactivity towards the homologous ras peptides. Investigation by limiting dilution analysis (LDA) revealed
different T-cell precursor frequencies for the immunising, mutant ras peptide (1:28 000), compared with the
normal ras peptide (1: 1 10 000).
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Somatic point mutations of K-ras oncogenes occur in
approximately 90% of pancreatic adenocarcinomas (Almo-
guera et al., 1988). Activating point mutations of K-ras
oncogenes predominantly occur at codons 12, 13 or 61 and
result in corresponding single amino acid substitutions within
the p21 protein. In pancreatic adenocarcinomas, the
mutations most commonly occur at codon 12 of K-ras, and
the spectrum of different amino acid substitutions is limited
(Capella et al., 1991). The mutations disrupt the normal
signalling function of p21 ras and contribute to malignant
transformation (Seeburg et al., 1984; Der et al., 1985).
Mutant p21 ras are not expressed by normal tissue and thus
represent true tumour-specific antigens. Mutant ras proteins
or corresponding peptide sequences have previously been
shown to be immunogenic both in healthy individuals (Jung
and Schluesener, 1991) and in cancer patients (Gedde-Dahl et
al., 1992a; Fossum et al., 1994). Most responding T cells have
been of the CD4+ phenotype, and their peptide specificity has
been described in detail (Gedde-Dahl et al., 1993). Ras
peptide binding to HLA class II molecules seems to be
promiscuous (Gedde-Dahl et al., 1994; Johansen et al., 1994)
and involves class II molecules of all isotypes (Fossum et al.,
1993). Also, human CD8 + TLCs specific for a single ras
mutation and capable of killing tumour cells harbouring the
same mutation have been described (Fossum et al., 1995).
Together these results suggest that ras peptide vaccination of
cancer patients with a verified ras mutation, might be applied
as a therapeutic principle of specific immunotherapy.
In a pilot clinical study, we have vaccinated pancreatic
carcinoma patients with synthetic ras peptide-pulsed auto-
logous antigen-presenting cells (APCs), and thereby induced
peptide specific T-cell responsiveness in vivo (Gjertsen et al.,
1995, 1996). To characterise the specificity further, HLA
restriction and functional properties of these in vivo activated
T cells, TLCs were generated from one of the vaccinated
patients. We report here that the vaccination procedure
resulted in a sufficient clonal expansion of CD4+ T cells
specific for the Glyl2-+Val mutation to allow detection in
peripheral blood and subsequent cloning. The HLA class II
molecules involved in binding and presenting of these
synthetic ras peptides to T cells in vivo were indentified in
antibody-blocking experiments and by using a panel of HLA-
homozygous B-lymphoblastoid cell lines (B-LCLs) as APC.
We also provide evidence that one of the CD4+ TLCs has
cytotoxic properties and is capable of specifically killing
autologous target cells pulsed with the appropriate ras
peptide. Different T-cell precursor frequencies against
mutant and normal ras peptides in peripheral blood were
determined by LDA.
Materials and methods
T-cell donors
The male patient (donor 1), 49 years old at diagnosis, had a
moderately differentiated, unresectable adenocarcinoma of
the pancreatic head. The HLA type of donor 1 was HLA-
A1,2; B8,35; DR3,6 (DRB1*0301,1401); DQ1,2 (DQA
1*0101,0501;DQB1*0201,0501,3). The K-ras mutation
Glyl2--Val was identified in DNA from formalin-fixed
paraffin-embedded tumour tissue using a highly sensitive
technique (Kahn et al., 1991). The female patient (donor 2),
39 years old at diagnosis, had a poorly differentiated,
unresectable adenocarcinoma of the pancreatic head with
one liver metastasis. The HLA type of donor 2 was HLA-
A3,19; B7,12; DR4,7; DQ2,3. The K-ras mutation in tumour
tissue from donor 2 was found to be Glyl2-.Asp. Both
patients were vaccinated with autologous ras peptide-pulsed
APC [freshly isolated, unfractionated peripheral blood
mononuclear cells (PBMCs)], and two and three rounds of
vaccination induced proliferative T-cell responses in PBMCs
of donor 1 and donor 2 respectively (Gjertsen et al., 1995).
Cells and media
PBMCs were prepared by centrifugation over Lymphoprep
(Nycomed, Oslo, Norway). B-LCLs used as APC were from
the 10th and 11th International Histocompatibility Work-
shop cell panels. The HLA profiles of the different cell lines
used are given in Table I. Autologous B-LCLs were
generated by Epstein-Barr virus transformation of B cells
from the patients. The tumour cell line K562 (erythroleu-
kaemia) was used as control cells in cytotoxicity assays. The
IL-2-dependent murine cytotoxic cell line CTLL-2 (Gillis et
al., 1978) was used as indicator cell line in LDA. All cultures
were grown in RPMI-1640 (Gibco, Paisley, UK) supplemen-
ted with gentamicin, 15% heat-inactivated human pool serum
(T cells) or 10% heat-inactivated fetal calf serum (FCS)
(Gibco) (cell lines). For the CTLL-2 cell line, we additionally
used human recombinant interleukin 2 (rIL-2) 5 U ml-'
(Amersham, Aylesbury, UK).
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Peptides encompassing residues 5-21 of p21 ras,
KLVVVGAGGVGKSALTI (single letter code), or with a
Gly to Val, Arg, Asp or Cys substitution at residue 12 or a
Gly to Asp substitution at residue 13, were synthesised and
purified as described earlier (Gedde-Dahl et al., 1992b). The
ras peptide spanning position 51-67 of p21 ras, CLLDILD-
TAGQEEYSAM, was used as a control in some experiments.
The peptides were dissolved in sterile water before filter
sterilisation.
Antibodies
Standard monoclonal antibodies (MAbs) against non-
polymorphic determinants of HLA class II were used: SPV-
L3 (anti-HLA-DQ) (a gift from Dr H Spits, Palo Alto, CA,
USA); B8.11 (anti-HLA-DR) (a gift from Dr B Malissen,
Marseille, France) and B7/21 (anti-HLA-DP) (a gift from Dr
F Bach, University of Minnesota, Minneapolis, MN, USA).
MAbs used for phenotyping of CD4+ (66.1) and CD8+ (ITI-
5C2) TLCs were used as described earlier (Gaudernack and
Lundin, 1989).
Generation of T-cell clones
Responding PBMCs from donor 1 were plated 2 x 106 cells
per well in 24-well plates (Costar, Cambridge, MA, USA)
and stimulated with the 12Val peptide at 25 gM. On day 9,
cloning of T-cell blasts by limiting dilution was performed. T-
cell blasts were counted in the microscope and seeded at five
blasts per well onto Terasaki plates (Nunc, Roskilde,
Denmark). As feeder cells, 20 x 103 autologous, irradiated
(30 Gy) PBMCs were used, and the cells were propagated
with the 12Val peptide at 25 gM and rIL-2, 5 U ml-'
(Amersham). After 9 days, TLCs were transferred onto flat-
bottomed 96-well plates (Costar) with 1 pg ml-' phytohae-
magglutinin (PHA, Wellcome, Dartford, UK), 5 U ml-' rIL-
2 and allogeneic, irradiated (30 Gy) PBMCs (2 x 105) per
well as feeder cells. After 6 days, TLCs were transferred to
24-well plates with PHA/rIL-2 and 1 x 106 allogeneic,
irradiated PBMCs as feeder cells and screened for peptide
specificity after 4-7 days.
Proliferative assay
In proliferative assays, B-LCLs used as APCs were irradiated
(100 Gy) and seeded (5 x 104 cells per well) in 96-well U-
bottomed microtitre plates (Costar). Peptides were added at a
final concentration of 15 gM and the cells were incubated for
at least 2 h at 37°C before addition of T cells (2-5 x 104). In
antibody-blocking experiments, APCs were incubated with
MAbs for 1 h at 37°C before addition of T cells. Final
concentrations of MAbs were 10 p,g ml-'. Proliferation was
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measured at day 3 after co-incubation with 3.7 x 104 Bq
[3H]thymidine (Amersham) 18 h before harvesting. Values are
given as mean counts per minute (c.p.m.) from tripli-
cates+standard deviation (s.d.). An antigen-specific response
was considered positive when the stimulatory index (SI) (i.e.
response with antigen divided by the response without
antigen) was above 3.
Cytotoxicity assay
Autologous B-LCLs were pulsed overnight with peptide at a
concentration of 25 gM, then washed and labelled with
7.5 MBq 5"Cr and FCS in a total volume of 0.5 ml at 37C
for 1 h, with gentle shaking every 15 min. Target cells were
washed three times, and seeded (2 x 103 cells per well) in 96-
well U-bottomed microtitre plates (Costar). Effector cells
were added at different numbers as indicated. In antibody-
blocking experiments, target cells were incubated with MAbs
for 30 min at 37°C before addition of T cells. MAbs were
used at a final concentration of 10 ,ug ml-'. Maximum and
spontaneous 5'Cr release of target cells was measured after
incubation with 5% Triton-X or medium respectively.
Supernatants were harvested after 4 h incubation at 37°C
and radioactivity was measured by gamma spectrometry
(Wallac 1470 Wizard). Percentage of specific chromium
release was calculated by the formula:
(Experimental release-spontaneous release): (Maximum
release-spontaneous release) x 100.
Spontaneous release was always below 20% of the maximum
release.
Limiting dilution analysis
The limiting dilution microculture conditions were adapted
from a method of IL-2 detection described previously (Orosz
et al., 1987). Briefly, irradiated (30 Gy) PBMCs (1 x 105)
were plated in replicate 96-well U-bottomed microtitre plates
(Costar) and allowed to adhere. After incubation for 2 h at
37°C, the plates were washed twice to remove non-adherent
cells. The washed, adherent cells (stimulator cells) were
pulsed with peptides at a concentration of 25 jgM before
addition of PBMCs (responder cells) in replicate sets of 12
microwells for each of seven, 2-fold serial responder cell
dilutions starting with 5 x 104 cells per well. After 24 h of
incubation at 37°C in 5% carbon dioxide, CTLL-2 cells
(2 x 103) were added to each well. After another 18 h, the
wells were pulsed with 3.7 x 104 Bq [3H]thymidine
(Amersham) for 6 h before harvesting. Estimates of the T-
cell precursor frequencies were calculated by analysis of the
Poisson distribution relationship between the number of
responder PBMCs added and the percentage of replicate
Table I The ability of different HLA homozygous cell lines to present the p21-ras-derived 12 Val peptide to TLC 42-4 and 69-29
HLA class II TLC 42-4 TLC 69-29
APC DRBI DQA1 DQBI c.p.m.a Slb c.p.m.a Slb
EK 9054 *1401 *0101 *05031 21116 70 1001 1.4
TEM 9057 *1401 *0101 *05031 22546 68 989 1.3
31227ABO 9061 *1401 *0101 *05031 17692 59 567 1.6
VAVY 9023 *0301 *0501 *0201 720 1.5 7327 10
STEINLIN 9087 *0301 *0501 *0201 NTC NT 31449 41
PF04015 9088 *0301 *0501 *0201 NT NT 39132 66
BOLETH 9031 *0401 *0302 *0302 1519 1.5 1184 1.8
OMW 9058 *1301 *0103 *0603 1587 1 1183 1.3
WT47 9063 *1302 *0102 *0604 1391 2.3 1289 1.6
EBd *0301/*1401 *0101/*0501 *0201/*05031 17695 55 40048 58
Figures in bold type show HLA-types shared with the patient. a Counts per minute, mean values of triplicates. Standard deviation usually less
than 10%. bStimulatory index; defined asmean c.p.m. in triplicates with antigen divided bymean c.p.m. incultures without antigen. cNT, not tested
in this assay. dAutologues B-LCL. Responses considered positive are underlined. Peptide concentration was 15gIM.Immune responses after ras peptide vaccination
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wells that failed to produce detectable IL-2 (Taswell et al.,
1981). Wells were considered positive for IL-2 production
when [3H]thymidine incorporation exceeded the mean of the
background plus three s.d.
Results
Specificity and HLA restriction of T-lymphocyte clones
In donor 1, a proliferative T-cell response against the ras-
derived 12Val peptide was induced after two rounds of
vaccination with peptide-pulsed autologous APC (Gjertsen et
al., 1995). The proliferative T-cell response in PBMCs was
detected in a standard 7 day proliferation assay. Responding
T cells were cloned by limiting dilution from a bulk culture
initiated after the proliferative response was observed, and
several TLCs of both the CD4+ and CD8+ phenotype were
obtained. TLC 42-4 is CD3+, CD4+, TCR x,#f and specific
for the 12Val peptide (Figure 1). Antibody-blocking studies
revealed that TLC 42-4 was HLA class II restricted, and that
the 12Val peptide was presented by HLA-DR, since MAbs
against DR but not DQ or DP abolished the response
(Figure 1). Donor 1 was heterozygous for DR and genomic
HLA-typing showed that DRB1 *0301,1401 was present. By
employing a panel of homozygous B-LCLs as APC, DRB1
*1401 was identified as the restriction element of TLC 42-4
(Table I). Another TLC 69-29 generated from donor 1 after
a
TLC 42-4
four rounds of peptide vaccination, is also CD3, CD4+,
TCR a,,B and specific for the 12Val peptide (Figure 2).
Studies with MAbs identified HLA-DQ as the antigen-
presenting molecule of TLC 69-29, since MAbs against DQ
and not DR or DP abolished the response (Figure 2). Panel
studies using homozygous B-LCLs identical to DQA1 and
DQB1 of donor 1 showed that DQBI*0201 is the restriction
molecule of TLC 69-29 (Table I).
Cytotoxicity of CD4+ T cells against peptide-pulsed EBV-
transformed B cells
To determine if the TLC 42-4 from donor 1 could lyse
autologous B-LCLs presenting the immunising 12Val peptide,
we pulsed autologous B-LCLs with the 12Val peptide and the
12Gly peptide (unmutated sequence) at 25 gM, and
performed a standard 4 h 5'Cr release assay. As shown in
Figure 3, the TLC 42-4 was capable of lysing autologous
target cells when pulsed with the 12Val peptide, but when B-
LCLs were pulsed with the control 12Gly peptide, no lysis
was observed. Specific lysis was observed at all effector-
target cell ratios tested. The cytotoxic effect of TLC 42-4 was
not caused by lymphokine-activated killer (LAK) cell activity,
since the natural killer (NK)LAK target K562 was not lysed
(data not shown). Furthermore, cytotoxicity was blocked by
anti-HLA DR MAbs, demonstrating that direct interaction
between the TLC 42-4 and the autologous target cell was
a TLC 69-29
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Figure 1 Specificity of TLC 42-4 for the immunising ras peptide
12Val (a), and blocking of the ras-specific response by anti-HLA-
DR MAb (b). MAbs against HLA-DR (B8/11), HLA-DQ
(SPVL-3) and HLA-DQ (B7/21) were used at final concentra-
tions of 10tgml-'. The peptides were used at a final
concentration of 15 pM. c.p.m., counts per minute.
Figure 2 Specificity ofTLC 69-29 for the immunising ras peptide
12Val (a), and blocking of the ras-specific response by anti-HLA-
DQ MAb (b). MAbs against HLA-DR (B8/11), HLA-DQ
(SPVL-3) and HLA-DQ (B7/21) were used at final concentra-
tions of 10pgml- The peptides were used at a final
concentration of 15 gM.
No peptide
12GIy
12Val
12Asp
12Arg
12Cys
l3Asp
0
b
No peptide
12Val
Anti-HLA-DR
Anti-HLA-DQ
Anti-HLA-DP
0Immune responses after ras peptide vaccinationa
MK Gjertsen et a! fI
1831
II
10 000 20 000 30 000
Mean c.p.m. [3H]-thymidine incorporation
10
n
_
50/1 25/1
E/T ratio
12.5/1 6.25/1
Figure 3 Cytotoxicity of TLC 42-4 against autologous B-LCL
pulsed with the immunising 12Val peptide (0) or the non-
mutated 12Gly peptide (ER) at 25 iM. Cytotoxic activity was
determined in a 4h 51Cr release assay. E/T ratio, effector-target
ratio.
required for lysis (data not shown). We were, however,
unsuccessful in establishing a tumour cell line from the ascites
fluid of the patient, and could, therefore, not evaluate a
possible cytotoxic effect on the autologous tumour cells.
Determination ofdifferent T-cell precursor frequencies against
mutant and normal ras peptides in peripheral blood
In donor 2, a proliferative T-cell response against mutant ras-
derived peptides was induced after three rounds of peptide
vaccination. The time span from onset of treatment until
detection of responding T cells in peripheral blood was,
however, approximately 40 days in both patients (Gjertsen et
al., 1996). The responding T cells from donor 2 were
characterised by cross-reactivity to all the homologous ras
peptides tested encompassing position 12, including the non-
mutated ras peptide (Figure 4). We made several attempts to
clone these cross-reactive T cells, but were not successful. To
sort out whether these cross-reacting T cells in PBMCs were
made up of one set of T cells that cross-reacted with the
homologous peptides or actually consisted of two or more
sets of T cells that reacted specifically to the different
peptides, a LDA was set up to investigate different T-helper
cell precursor frequencies. We found a T-cell precursor
frequency of 1: 28 000 PBMCs for the immunising 12Asp
peptide compared with a T-cell precursor frequency of
1:110 000 PBMCs for the 12Gly peptide expressing normal
ras (Figure 5). These results suggest that ras peptide
immunisation of this donor may have produced a clonal
expansion of at least two different sets of T cells, since the T-
cell precursor frequencies are not identical.
Discussion
Cancer vaccines based on defined peptide epitopes are now
being tested in a number ofclinical trials. In these approaches
it is of great importance to characterise the in vivo activated T
cells of the responding patients after peptide vaccination.
Here, we report that the induction of 12Val peptide-
responsive T cells in the pancreatic carcinoma patient after
mutant ras peptide vaccination resulted in a sufficient
expansion of CD4+ T cells specific for the 12Val peptide to
allow cloning of these T cells in vitro. Our vaccination
strategy is based on earlier observation that ras peptide
Figure 4 Proliferative T-cell response in PBMC from donor 2
after mutant ras peptide vaccination with the 12Asp peptide. T-
cell proliferation in PBMC from this patient was first obtained
after three cycles of peptide vaccination and was characterised by
cross-reactivity towards the homologous ras peptides encompass-
ing position 12. The proliferative T-cell response was tested in a
traditional 7 day proliferation assay at a final peptide
concentration of 30[M.
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Figure 5 Estimation of different T-cell precursor frequencies in
PBMC from donor 2 against the immunising 12Asp peptide (*)
compared with the non-mutated 12Gly peptide (LI). The
responder cells were tested in replicate sets of 12 microwells for
each of seven, 2-fold serial responder cell dilutions starting with
5 x 104 cells per well. Final peptide concentration was 12.5,UM.
binding to HLA class II molecules is highly promiscuous
(Gedde-Dahl et al., 1994; Johansen et al., 1994), indicating
that a majority of cancer patients will carry one or more
HLA class II molecules capable ofbinding and presenting the
mutant ras peptide used for vaccination. Demonstrating of
HLA-DR6 and DQ2 as ras peptide-presenting molecules in
this patient supports this concept, since neither DR6 nor
DQ2 have earlier been shown to bind or present ras peptides
to T cells.
None of the five patients demonstrated a T-cell response
towards the K-ras mutation found in their tumour before
vaccination (Gjertsen et al., 1995). This could theoretically
result from tolerance induction, leading to inactivation of T
cells with the appropriate receptor. However, our results
demonstrate that the lack of T-cell responsiveness observed
initially in these patients was not due to absence of specific T
cells in the repertoire or lack of HLA-molecules with
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appropriate binding capacity, since a ras peptide-specific
response could be induced upon vaccination. These results
suggest that the state of unresponsiveness towards peptides
expressing mutated K-ras epitopes may be overcome by
peptide immunisation. The method of vaccination chosen in
our approach is based upon loading of professional APCs
with synthetic ras peptides ex vivo in order subsequently to
present a tumour-specific epitope in an immunogenic context
in vivo. Clearly, in two of our patients with terminal disease,
including a large tumour burden, these peptide-loaded APCs
were capable of initiating an immune response, and thus
breaking a possible state of functional tolerance. The present
approach is relatively crude, since we used freshly isolated,
unfractionated PBMCs containing a small fraction of
dendritic cells (DCs). Presumably, the peptide-loaded DCs
are the active components of the vaccine. In future studies
purified, freshly isolated or in vitro expanded DCs may prove
more efficient. This last approach has recently been described
for a MAGE-I peptide vaccination protocol, and was found
to induce a T-cell response in vivo (Mukherji et al., 1995).
The clinical importance of the induced K-ras mutation-
specific T cells remains to be established. Theoretically,
CD4+ ras-specific T cells may influence the growth of the
tumour in two different ways, either indirectly by recognising
processed p21 ras protein taken up by professional APC
residing in the tumour microenvironment, or directly by
recognising a ras peptide presented by HLA class II
molecules on the tumour cell itself. In the indirect
mechanism, activation of the CD4+ T cell may result in the
initiation of an effector cascade involving CD8+ effector T
cells specific for a variety of tumour-specific or associated
antigens. A number of such T-cell epitopes have now been
defined for melanomas (Boon et al., 1994), but so far not for
pancreatic adenocarcinomas. In the direct mechanism, the
CD4+ T cell may kill the tumour cell following induction of
HLA class II molecules on the tumour cells by cytokines
released during an indirect immune recognition phase. In an
attempt to study the potential functional role of the induced
K-ras mutation-specific T cells, we performed some studies
with peptide-pulsed B-LCLs as target cells. This approach
was chosen, since we did not have cancer cells or cell lines
from the patient available for functional studies. With these
'surrogate' tumour cell lines expressing the appropriate ras
peptide, we were able to demonstrate that in vivo activated T
cells were potent killer cells. Killing was specific, since target
cells pulsed with the non-mutated peptide were not killed.
This indicates that activated, K-ras mutation-specific T cells
may have a direct functional importance as killer cells in vivo,
even though they are of the T-helper phenotype (CD4+).
Consistent with that contention, human CD4+ T-cell lines,
generated by in vitro stimulation with mutant ras peptides,
have been shown to be able efficiently to kill B-LCLs
transduced with the corresponding p21 ras oncogene (Tsang
et al., 1994). Future studies with HLA-matched tumour cell
lines will hopefully allow a more detailed knowledge of the
functional properties of these in vivo activated, cytotoxic T
cells.
The difference between the mutant ras peptides and the
peptide representing normal p21 ras is only one amino acid in
position 12, and can give rise to T cells that may show
varying degrees ofcross-reactivity (Gedde-Dahl et al., 1992b).
This presents the possibility that some T cells may be
autoreactive and, therefore, potentially harmful. In our pilot
clinical study (Gjertsen et al., 1996) this did not seem to be
the case, since no side-effects or possible autoreactivity were
observed in the patient having cross-reactive T cells. In a
mouse model system, where CD8+ T cells specific for
different ras epitopes were induced following immunisation
with a ras-vaccinia virus construct, only T cells specific for
mutant ras were able to lyse target cells harbouring a ras
mutation (Skipper et al., 1993), indicating that endogenous
expression of p21 ras by normal cells may only result in
subthreshold amounts of ras peptide and is therefore
insufficient for T-cell recognition. In this context, it is of
importance that in many cases of human malignancies, the
ras oncogene family seems to be overexpressed compared
with normal tissues (Slamon et al., 1984; Spandidos and
Kerr, 1984). The basis for the cross-reactivity against the
common mutations in position 12, as well as against the
peptide expressing normal ras observed in donor 2, seemed to
be a result of in vivo activation of a set of T cells, which was
cross-reactive. The precursor frequency of these cells
(1:110 000) was lower than the precursor frequency of T
cells recognising the Asp12 mutation. This precursor
frequency may be too low to cause any side-effects in the
form of autoimmunity.
In conclusion, we have shown that ras peptide vaccination
of patients with pancreatic adenocarcinoma can result in the
induction of T cells specific for combinations of ras peptides
and HLA class II molecules not previously demonstrated.
These T cells are functionally active and can kill autologous
peptide-pulsed target cells specifically. Such T cells may be of
clinical benefit to patients with minimal residual disease.
Studies are currently under way to test this approach in
patients with colorectal adenocarcinoma and pancreatic
adenocarcinoma after surgery.
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